Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 1, 1996, Pages 43-50

  Srivastava, Suresh C ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; RADIOISOTOPE;

CANCER RADIOTHERAPY; DRUG TARGETING; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW;

EID: 0030011011     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.43     Document Type: Review

References (47)

1. Srivastava SC (ed.), Radiolabeled Monoclonal Antibodies for Imaging and Therapy, Plenum Press, New York, 1988
2. Larson SM, Digvi CR, Scott A, et al. Current status of radioimunotherapy. Nucl Med Biol 1994;21:785-792.
3. Mausner LF and Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys 1993; 20:503-509.
4. Adelstein SJ, Kassis AI Radiobiologic implications of the microscopic distribution of energy from radionuclides. Nucl Med Biol 1987;14:165-169
5. Jungerman JA, Yu Kin-Hung P, and Zanelli CI. Radiation absorbed dose estimates at the cellular level for some electron emitting radionuclides for radioimmunotherapy Int J Appl Radiat Isot 1984;35:883-888.
6. Wessels BW and Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor-associates antibodies. Med Phys 1984;11:638.
7. Humm JL Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986,27:1490-1497.
8. Griffith MH, Yorke ED, Wessels et al. Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med 1988;29:1795-1809.
9. Srivastava SC and Meinken GE Correlating labeling chemistry and in vitro test results with the biological behavior of radiolabeled proteins. Int J Biol Markers 1986,1:111-120.
10. Order SE, Klein JL, Leichner P, et al. Yttrium-90 antiferritin. A new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 1986,12.227-231.
11. Kosmas C, Maraveyas A, Gooden CS, Snook D, and Epenetos AA. J. Antichelate antibodies after intraperitoneal Y-90 labeled monoclonal antibody immunoconjugates for overian cancer therapy. J Nucl Med 1995;36:746-753.
12. Carasquillo JA, Kramer B, Fleisher T, et al. In-111 versus Y-90 T101 biodistribution in patients with hematopoietic malignancies. J Nucl Med 1991:32:970.
13. 2 fragment for radioimmunotherapy in solid tumors. J Nucl Med 1990;31:724.
14. Srivastava SC, Mausner LF, and Mease RC. Criteria for the selection of radionuclides for tumor radioimmunotherapy. In: Synthesis and Applications of Isotopically Labeled Compounds, E. Buncei & G.W. Kabalka, Editors, Elsevier, New York, 1992, pp. 116-121.
15. Srivastava SC and Mausner LF. Production and supply of radioisotopes with high-energy particle accelerators: Current status and future directions: In: Proc. 21st Japan Conf. Radiat. and Radioisotope, Feb. 2-4, 1994, Japan Atomic Industrial Forum, B-550, pp.1-11.
16. Mausner LF, Mirzadeh S, Schnakenberg H, Srivastava SC. The design and operation of the upgraded BLIP facility for radionuclide research and production. Appl Radiat Isotopes 1990;41:367-374.
17. Volkert WA, Goeckler WF, Ehrhardt GJ, and Ketring AR. Therapeutic radionuclides: production and decay property considerations. J Nucl Med 1991,32:174-185.
18. O'Donoghue JA, Bardies M, and Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta emitting radionuclides J Nucl Med 1995;36:1902-1909.
19. Tilyou SM. Energy agency examines radioisotope needs in preparation for the future. J Nucl Med 1990;31:13A.
20. Isotopes for Medicine and the Life Sciences, Adelstein SJ and Manning FJ Editors, National Academy Press, Washington, D.C., 1995.
21. Proceedings of the DOE Workshop on "The Role of a High-Current Accelerator in the Future of Nuclear Medicine". Los Alamos, NM, Conference LA 11576-C, 1989.
22. Proceedings of the Purdue NBTF Workshop, Purdue University, West Lafayette, IN, 1992.
23. Srivastava SC, Meinken GE, Mausner LF, Cutler, C, Atkins HL, and Deutsch E. In: Technetium and Rhenium in Chemistry and Nuclear Medicine, M. Nicolini, et al, editors, SG Editoriali, Padova, 1994, pp. 287-292.
24. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ, and D'Alessandro T J. Tin-117m(4+)-DTPA for palliation of bone from osseous metastases: A pilot study. J Nucl Med 1995;36:725-729.
25. 117mSn with the Szilard-Chalmers process J Labelled Compds Radiopharm 1989;16:177-178.
26. Larson SM, Pentlow KS, Volkow ND, et al. PET scanning of 1-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 1992;33:2020-2023.
27. Zalutsky MR and Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Appl Radiat Isot 1988;39:227.
28. Reugg CL, Anderson-Berg WT, Brechbiel M, Mirzadeh S, Gansow OA, and Strand M. Improved in vivo stability and targeting of bismuth labeled antibody. Cancer Res 1990;50:4221-4226.
29. Rakowicz-Szulczynska EM, Steplewski Z, and Koprowski H. Amer J Pathol 1992;141:937-957.
30. Steplewski Z and Rakowicz-Szulczynska EM. Personal communication.
31. 117mSn with the Szilard-Chalmers process Nucl Med Biol 1991;18:589-603.
32. Zalutsky MR. Radiohalogenation of antibodies: Chemical aspects In: Radiolabeled Monoclonal Antibodies for Imaging and Therapy, Srivastava SC, Ed., Plenum, New York, 1988, pp. 195-213.
33. Seevers RH and Counsell RE. Radioiodination techniques for small organic molecules. Chem Rev 1982;82:575.
34. Griffiths GL, Knapp Jr FF, Callahan AP, et al.The use of Re-188 from an in-house W-188/Re-188 generator for the ready preparation of Re-188-labeled monoclonal antibodies J Nucl Med 1991;32:1098.
35. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistribution of yttrium- and indium-labeled monoclonal antibody B72 3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989;30:672-689.
36. Adams GP, DeNardo SJ, Deshpande SV, et al. Dual isotope pharmacokinetics of an antiiymphoma antibody (LYM-1) with a new bifunctional chelating agent. J Nucl Med 1990;31:823.
37. Mausner LF, Kolsky KL, Mease RC, Chinol M, Meinken GE, Straub RF, Pietrelli L, Steplewski Z, Srivastava SC. Production and evaluation of Sc-47 for radioimmunotherapy. J Labelled Compds Radiopharm 1993;32:388-390.
38. Mease RC, Meinken GE, Srivastava SC, Mausner LF, and Steplewski Z Synthesis and evaluation of 4-isothiocyanato- and 4-bromoacetamido cyclohexyl EDTA (4-ICE and 4-BACE): Two new bifunctional chelating agents for preparing radiometal immunoconjugates. J Nucl Med 1991;32:1023.
39. Srivastava SC, Mease RC, Meinken GE, Gestin JF, Joshi V, Pyatt B, Mausner LF, and Chatal JF Reduction in non-specific uptake of indium-111 from using semi-rigid cyclohexyl EDTA immunoconjugates. J Labelled Compds Radiopharm 1994;35:303.
40. Mausner LF, Joshi V, Kolsky KL, Meinken GE, Mease RC, and Srivastava SC. Evaluation of chelating agents for radioimmunotherapy with scandium-47 J Nucl Med 1995;36:104P.
41. Moi MK, Meares CF, McCall MJ, et al. Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 1985;148:249.
42. Moi MK, Meares CF, and DeNardo SJ The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″N‴ -tetraacetic acid and study of its yttrium (IIi) complex. J Am Chem Soc 1988;110:6266.
43. Morphy JR, Parker D, Alexander R, et al. Antibody lebelling with functionalized cyclam macrocytes. J Chem Soc Chem Comm 1988;156.
44. Macke H, Ruser G, Koch P, et al. New bifunctional chelators for antibody labeling with metallic radionuclides J Labelled Compds Radiopharm 1991;30:318.
45. Kukis DL, DeNardo SJ, DeNardo GL, et al. Effect of the extent of substitution on the immunoreactivity of 2IT-BAT-LYM-1 immunoconjugate. J Nucl Med 1994;35:259P.
46. Boniface GR, Izard ME, Walken KZ, et al. Labeling of monoclonal antibodies with samarium-153 for combined radioimmunoscintigraphy and radioimmunotherapy. J Nucl Med 1989;30:683-691.
47. Cacheris WP, Nickle SK and Sherry AD. Thermodynamic study of lanthanide complexes of 1,4,7-triazacyclononane-N,N,′,N″,N‴-tetraacetic acid. Inorg Chem 1987;26:958.